Clostridium difficile

Clostridium difficile
Scientific classification
Kingdom: Prokaryote Phylum: Firmicutes Class: Clostridia Order: Clostridiales Family: Clostridiaceae Genus: Clostridium Species: Difficile
Binomial name
Clostridium difficile

Clostridium difficile is a spore-forming, anaerobic, toxin-producing bacterium that is a "common inhabitant of the colon flora in human infants and sometimes in adults. It produces a toxin that causes pseudomembranous enterocolitis in patients receiving antibiotic therapy." C. difficile superinfection after oral antibiotic therapy, leading to potentially fatal pseudomembranous enterocolitis, has been an increasingly severe public health problem. Indeed, many primary physicians now consider it wise to warn outpatients on antibiotics to seek immediate consultation if they develop severe diarrhea.

C. difficile is present at low levels in the gut flora of about 3% of adults. These people however show no symptoms and do not need to be treated. The infection occurs when a person is treated with antibiotics targeted against other bacteria. The disease is for the most part nosocomial. Patients who are hospitalized come in contact and are often inoculated with the bacteria. When the patient is treated with antibiotics, especially those with a broad range of activity, the normal gut flora is disrupted, and C. difficile, with its multi-drug resistance, experiences overgrowth. The bacteria releases large quantities of enterotoxins (toxin A) and cytotoxins (toxin B), causing pseudomembranous enterocolitis.

scanning electron micrograph of C. difficile

History

In 1935, Hall and O’Toole first isolated the bacteria from the stools of newborns and described it. They named it Bacillus difficilis because it was hard to isolate and grew very slowly in culture.

C. difficile is an important pathogen that is currently increasing in its prevalence world-wide. A complete genome sequence would enable geneticists to come up with a more direct and efficient treatment against the pathogen. The genetic material encodes for antimicrobial resistance, production of toxins (virulence), host interaction (adaptations for survival and growth within the gut environment), and the production of surface structures. The understanding of how these genes interact with their environment will be useful in developing therapies against C. difficile associated diseases.

Genome Structure

Sebaihia et al (2006) determined the complete genomic sequence of C. difficile strain 630, a highly virulent and multidrug-resistant strain. It was found that the genome consists of a circular chromosome of 4,290,252 bp and a plasmid, pCD630, of 7,881 bp. The chromosome encodes 3,776 predicted coding sequences (CDSs), with resistance, virulence, and host interaction genes, while the plasmid carries only 11 CDSs, none of which has any obvious function. C. difficile has a highly mobile genome, with 11% of the genome consisting of mobile genetic elements, mostly in the form of conjugative transposons. Conjugative transposons are mobile genetic elements that are capable of integrating into and excising from the host genome and transferring themselves, and are responsible for the evolutionary acquisition by C. difficile of genes involved in resistance, virulence, and host interactions. Some of the mobile elements are prophage sequences. Host interaction genes involve genes that code for metabolic capability adaptations for survival and growth within the gut environment.

The genome carries several copies of a very interesting genetic element, the IStron. The IStron is a hybrid between an intron and an insertion sequence (IS), and can therefore insert itself into a DNA sequence, and later be excised from the primary mRNA transcript by cellular machinery. For example, a copy inserted in the tcdA gene (that encodes the enterotoxin A) renders the gene nonfunctional until the IStron is excised. Truncated copies of the IStron (containing only the IS sequence) were found in intergenic regions. Possibly, these truncated variants may be the answer to make C. difficile unable to produce functional toxins.

Cell structure and metabolism

Clostridia are Gram-positive, anaerobic, spore-forming, rod-shaped, motile bacteria. As spores, the bacteria look like drumsticks, with a bulge located at one end. C. difficile produces an S layer (polysaccharide capsule) that contributes to its pathogenicity. C. difficile has flagellae that contribute to its motility.

C. difficile is an obligate fermenter, and exhibits optimal growth in blood agar at human body temperatures in the absence of oxygen. The metabolism of C. difficile is in large part adapted to life in the intestinal tract. It produces enzymes that degrade nutrients abundant in the intestine. Carbohydrates are the preferred nutrient source, and C. difficile has the ability to metabolize a wide range of carbohydrates. The bacteria also have a relatively unique ability to utilize ethanolamine, an abundant phospholipid provided by the host’s dietary intake, as a carbon and nitrogen source.

C. difficile has the enzyme that catalyzes the decarboxylation of p-hydroxyphenylacetate (a tyrosine degradation product) to p-crysol, a compound that stunts bacterial growth. C. difficile produces and tolerates high concentrations of p-crysol, giving it a competitive advantage over the normal bacterial flora in the intestine. '

Ecology

C. difficile is found throughout nature, especially in soil. It exhibits optimal growth in blood agar at human body temperatures in the absence of oxygen. It can remain dormant in hospitals in the form of spores until patient inoculation. Following treatment of antibiotics, C. difficile overgrows in the intestinal tract, causing pseudomembranous enterocolitis, and consequently diarrhea.

Pathology

C. difficile is transmitted from person to person by the fecal-oral route in the form of vegetative cells and heat-resistant spores. Most vegetative cells are killed in the stomach, but spores pass through the stomach unaffected because of their acid resistance. Spores germinate in the small bowel upon exposure to bile acids. C. difficile multiplies in the colon and overgrows in the absence of competitors (following antibiotic treatment). Mucosa of the gut allows C. difficile adherence to the colonic epithelium.

Different pathogenic strains of C. difficile produce different toxins, but the most common ones are enterotoxin (toxin A) and cytotoxin (toxin B). The two toxins lead to "the production of tumour necrosis factor-alpha and pro-inflammatory interleukins, increased vascular permeability, neutrophil and monocyte recruitment, opening of epithelial cell junctions and epithelial cell apoptosis." Hydrolytic enzymes cause connective tissue to degrade, leading to colitis, pseudomembrane formation and watery diarrhea. Toxin B is thought to be essential for disease to occur.

Risk factors for acquisition include use of proton pump inhibitor medications.

Clostridium difficile infection (CDI) can range in severity from asymptomatic to life threatening. Death is more common among the aged (>65). Patient symptoms include severe diarrhea, exposure to antibiotics, foul stool odor, and abdominal pain.

Pseudomembranous enterocolitis, a CDAD

Diagnosis

Clinical practice guidelines address diagnosis.

Two clinical prediction rules suggests which patients will have positive toxin results. Unfortunately, neither of these studies used the sensitive polymerase chain reaction as a reference standard.

• Clostridium difficile is very unlikely among patients "without a history of antibiotic use and either significant diarrhea or abdominal pain."

Suggestive medical history

A history of exposure to antibiotics in the last 30 days is present in most all patients.

Clostridium difficile should be suspected among patients with "clinically significant diarrhea, usually defined as 3 or more loose stools per day for at least 1 to 2 days". Significant diarrhea is defined as one day of "at least three partially formed or watery stools, 1 L of colostomy output, or more than 200 ml of watery rectal bad output" or "multiple or several loose stools."

Laboratory tests

The accuracy of laboratory tests is in the table.

Accuracy of stool tests for
presumed Clostridium difficile associated diarrhea

	Sensitivity	Specificity
Cytotoxin by enzyme immunoassay	73%	97%
Cell culture cytotoxin assay (tissue culture assay)	77%	97%
Real-time polymerase chain reaction for toxin B gene	93%	97%
Anaerobic culture (for toxigenic C. difficile strains)	100%	96%
Sigmoidoscopy (for pseudomembranes)	31%

Colonoscopy

Based on a few studies, most patients with Clostridium difficile associated diarrhea do not have pseudomembranous enterocolitis upon colonoscopy.

Treatment

Clinical practice guidelines and a systematic review address treatment.

Antibiotics

Randomized controlled trials of interventions for Clostridium difficile-associated diarrhea

Trial	Patients	Intervention	Comparison	Outcome	Results - cure		Results - recurrence
					Intervention	Control	Intervention	Control
Louie et al 2011	629 patients • mild to severe	Fidaxomicin • 200 mg twice daily • 10 days	Vancomycin • 125 mg 4 times/day • 10 days	stool toxin after 4 weeks	88%	86%	15%	25%
Zar et al 2007	150 patients • mild to severe	Metronidazole • 250 mg 4 times/day • 10 days	Vancomycin • 125 mg 4 times/ day • 10 days	stool toxin after 3 weeks	90% (76% if severe)	98% (97% if severe)	15%	14%

Various antibiotics have been studied in randomized controlled trials. Teicoplanin may be the most effective antibiotic. Vancomycin has an insignificant trend towards being better than metronidazole; metronidazole is likely to be the least expensive of the group and is not a last resort for other highly resistant organisms.

"Our findings suggest that metronidazole and vancomycin are equally effective for the treatment of mild CDAD, but vancomycin is superior for treating patients with severe CDAD." according to a randomized controlled trial.

In a randomized controlled trial, the relative risk ratio of fidaxomicin, as compared to vancomycin, for recurrence of C. difficile infection was 0.6 and the relative risk reduction was 40.0%. In populations similar to those in this study which had a rate of risk as measured by the recurrence of C. difficile infection of 25% without treatment, the number needed to treat is 10.

Consider vancomycin if the patient has two or more points from the following:

• 1 point for each of
  • WBC > 15k
  • albumin < 2.5
  • age > 60
  • temperature > 38.3° C
• 2 points for each of
  • Pseudomembranous colitis
  • Intensive care

It should be noted that vancomycin is given orally in this condition, and is not absorbed systemically. While it still needs to be used with care to avoid the development of resistant organisms, the risk may be lower than if it is used as a parenteral therapy for already resistant pathogens such as methicillin-resistant Staphylococcus aureus.

In a randomized controlled trial, the relative risk ratio of fidaxomicin, as compared to vancomycin, for recurrence of C. difficile infection was 0.6 and the relative risk reduction was 40.0%. In populations similar to those in this study which had a rate of risk as measured by the recurrence of C. difficile infection of 25% without treatment, the number needed to treat is 10.

A case series suggests tigecycline for severe disease.

Probiotics (administration of bacteria)

Probiotic administration may not treathelp according to a meta-analyses. Probiotics can be harmful among intensive care patients.

|title=Relapsing clostridium difficile enterocolitis cured by rectal infusion of homologous faeces |journal=Lancet |volume=2 |issue=8354 |pages=845 |year=1983 |month=October |pmid=6137662 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(83)90753-5 |issn=}}</ref> or colonoscopic infusion of feces helped according to case reports.

Monoclonal antibodies

In a randomized controlled trial, the relative risk ratio of adjunct treatment with monoclonal antibodies against C. difficile toxins, as compared to placebo, for recurrence of C. difficile infection was 0.3 and the relative risk reduction was 72.0%. In populations similar to those in this study which had a rate of risk as measured by the recurrence of C. difficile infection of 25% without treatment, the number needed to treat is 6.

Recurrent infection

Regarding the cause of recurrences:

• Second episode within 8 weeks, 88% are relapses
• Second episode after > 8 weeks, 65% are relapse

A clinical prediction rule found that recurrent infection is more likely if age is more than 65 years, the patient has severe or fulminant illness, and additional antibiotic exposure occurs after after treatment of the initial Clostridium difficile infection. Use of antacids may also be a risk factor for recurrence.

Asymptomatic carriage should not be treated according to a meta-analysis.

Antibiotics

Observational studies conflict regarding the best agent and suggest vancomycin may or may not be better than metronidazole. Various methods exist for the administration of vancomycin and metronidazole.

Cohort studies and case series of the treatment of Clostridium difficile associated diarrhea

	Patients	Intervention / duration	Comparison	Outcome: Recurrence rate
Approximately 2 weeks
Vancomycin constant dose	171 patients	0.5 to 2 grams daily 10 - 14 days	NA	40%
Metronidazole constant dose	115 patients	1.0 to 1.5 grams per day 10 - 14 days	NA	37%
Metronidazole constant dose	20 patients	Metronidzole 1200 mg daily 14 days	NA	45%
Vancomycin constant dose	83 patients	0.5 to 3 grams/day 10 - 16 days	NA	54%
high dose	21 patients	≥2 grams/day 10 - 16 days	NA	43%
medium dose	14 patients	1 - 2 grams/day 10 - 16 days	NA	71%
low dose	48 patients	< 1 grams/day 10 - 16 days	NA	54%
Metronidazole constant dose	36 patients	0.5 to 3 grams/day 10 - 16 days	NA	42%
Approximately 3 weeks
Vancomycin tapered dose	29 patients	Varying doses 21.5 ± 10.0 days	NA	31%
Vancomycin pulsed dose	7 patients	Varying doses 21 days	NA	14%
More than 3 weeks
Vancomycin followed by rifaximin	8 patients	Vancomycin of unknown duration followed by rifaximin 400–800 mg daily for 14 days ≥ 21 days	NA	13%
Vancomycin tapered & pulsed dose	22 patients	125 mg four times daily tapered to 125 mg every third day 42 days	NA	0%

Serial therapy with vancomycin and rifaximin has been studied in a small uncontrolled series of patients.

Administration of bacteria

Probiotics may help. However, probiotics can be harmful among intensive care patients.

Rectal or colonoscopic infusion of feces helped according to case reports.

Prevention

Administration of bacteria

Probiotic administration may prevent C diff diarrhea according to meta-analysis meta-analyses and a more recent randomized controlled trial. However, probiotics can be harmful among intensive care patients.

Rectal

Research

There is an ongoing search for new therapeutic strategies to battle the ever-increasing pathogenicity of the C. difficile strains. Barreto et al (2008) have recently released a study on the effects of the polysaccharide fucoidin, an L-selectin blocker, on toxin-A-induced mouse enteritis. Enteritis is medical term that refers to the inflammation of the intestine, usually accompanies by diarrhea. Fucoidin or the placebo (saline) was injected into the mouse, and 5 minutes later, toxin A was locally released. To measure the effect of fucoidin, intestinal fluid volume/length and ileal loop weight/length ratios were calculated three hours later. It was found that fucoidin significantly (P < 0.05) reduced the toxin-A-induced increase in weight/length and volume/length ratios and reduced mucosal disruption.

Gerber and Ackermann (2008) have published a report on another treatment option, OPT-80. OPT-80 (otherwise known as tiacumicin B, lipiarmycin or PAR-101) is “an antimicrobial with little or no systemic absorption after oral administration and narrow activity spectrum against Gram-positive aerobic and anaerobic bacteria.” OPT-80 is highly effective at very low concentrations, making it a very safe and efficient drug. More clinical trials are to be completed, but for now results look promising.

The reason why C. difficile-associated disease (CDAD) is becoming such a widespread nosocomial disease is because the spores it forms are resistant to heat, chemicals, antibiotics, and radiation, making the hospital environment difficult to sanitize. The study of C. difficile germination from spores to vegetative cells will shed light on the strengths and weaknesses of the spores, and will thus lead to the development of methods for spore eradication. Sorg and Sonenshein (2008) studied the effects of the components of bile on the germination of C. difficile spores. They found that cholate derivatives and glycine act to induce germination in the duodenum. It was found that, interestingly, deoxycholate, a metabolite of cholate (produced by the normal intestinal flora) induces germination while preventing growth of vegetative cells. This implies a mechanism by which normal gut flora can mediate the levels of vegetative C. difficile cells in the gut.